⇨ Yardley, PA-based OptiNose is joining the growing line for Nasdaq, filing for a $100 million IPO, according to the S-1. The filing came right on the heels of an OK for XHANCE — previously referred to by the development name OPN-375 — for the treatment of nasal polyps.
⇨ GSK got some good news today, winning FDA approval of the first three-in-one once-daily therapy for COPD. The move comes after the EMA endorsed the inhaler last week.
⇨ After nearly a decade spent collaborating with Celgene, Acceleron $XLRN says it has gained rights to develop sotatercept for pulmonary arterial hypertension, with plans to launch a Phase II study during the first half of next year.
⇨ The microcap biotech Juniper Pharmaceuticals $JNP is refocusing and reorganizing. The plan is to slash the staff roster by 8% and concentrate on “the core businesses of Crinone progesterone gel and Juniper Pharma Services” at the Boston-based women’s healthcare company.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.Free Subscription